Ono Pharmaceutical pays $80 million for Asian rights to Biohaven IgG degrader trio, including phase-3 Graves disease candidate

Japan's Ono Pharmaceutical has agreed to pay $80 million upfront for the rights to three Biohaven IgG degrader programs in Japan, South Korea, Taiwan and ASEAN markets. The agreement also includes a $20 million milestone payment and a 20% profit share on sales in those territories.

The lead asset, BHV-1300, is a protein degrader that selectively targets IgG1, IgG2 and IgG4 while sparing IgG3. It is being tested in a phase‑3 trial for Graves disease, and early data released in January showed complete suppression of disease‑causing TSH‑receptor antibodies in a patient.

The deal also covers two next‑generation degraders, BHV-1310 and BHV-1320, which build on the same technology platform developed at Yale University's Spiegel Lab. BHV-1300 is designed for self‑administration via an autoinjector.

Company officials said the partnership positions Ono to bring this innovative immune‑modulating approach to patients across Japan and key Asian markets.